MGC Pharma confirms highest-THC cannabis strain.


MGC Pharmaceuticals (ASX: MXC) (OTC: MGCLF) has announced confirmation that their strain contains an industry-high THC level of 35%.

First announced in on 1 February, the results have now been independently confirmed by the University of Ljubljana Biotechnical Facility and Pharma Lab in Slovenia.

While to a layman this might not seem significant, when compared to the top high-THC strains on the markets of Canada and USA, it exceeds competition.

Most high-THC strains are in the low-20% range, with Leafly reporting several OG strains as having the most THC: 28% – and CannabisIntel has not found a report of anything higher.

Along with the high-THC strain, MGC Pharma has also confirmed a high CBD strain containing over 20% CBD and <1% THC.

While MGC Pharma is not involved in the recreational use of cannabis, their high THC strain has significant impact on their operations and profitability.

MGC Pharma operates an eu-GMP certified facility in Slovenia, and currently has a range of phytomedicines and phytotherapeutics, all in oil form.

With their high-THC and CBD strains, MGC Pharma is able to deliver much larger yields in future cultivations, increasing output and lowering operational costs, which will flow on to a lower retail price for patients.

1 Comment

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Blaise Bratter
Blaise Bratter is the Chief Contributor to CannabisIntel. Being involved in the Australian cannabis industry since legalisation in 2016, he is now Operations Manager for ASX listed company MGC Pharmaceuticals.

Get all the latest content delivered straight to your inbox.”

%d bloggers like this: